Sicherheit und Wirksamkeit von Selonsertib bei Erwachsenen mit nicht-alkoholischer Steatohepatitis (NASH, auch Fettleber bezeichnet) und brückenbildender (F3) Fibrose (STELLAR 3)

Drug: SEL;Drug: Placebo to match SEL 6 mg;Drug: Placebo to match SEL 18 mg

Key Inclusion Criteria:

- Liver biopsy consistent with NASH and bridging (F3 fibrosis) according to the NASH
Clinical Research Network (CRN) classification in the opinion of the central reader

- Has the following laboratory parameters at the screening visit:

- Alanine aminotransferase (ALT) = 8 x upper limit of normal (ULN)

- Creatinine Clearance (CLcr) = 30 milliliter/minute (mL/min), as calculated by the
Cockcroft-Gault equation

- Hemoglobin A1c (HbA1c) = 9.5% (or serum fructosamine = 381 µmol if HbA1c is
unable to be resulted)

- Total bilirubin = 1.3 x ULN (unless an alternate etiology such as Gilbert's
syndrome or hemolytic anemia is present)

Key Exclusion Criteria:

- Prior history of decompensated liver disease including clinical ascites, hepatic
encephalopathy (HE), or variceal bleeding

- Child-Pugh (CP) score > 6, as determined at screening, unless due to therapeutic
anti-coagulation

- Model for End-stage Liver Disease (MELD) score > 12, as determined at screening,
unless due to therapeutic anti-coagulation

- Other causes of liver disease including, but not limited to, alcoholic liver disease,
hepatitis B, hepatitis C, autoimmune disorders, drug-induced hepatotoxicity, Wilson
disease, iron overload, and alpha-1-antitryspin deficiency, based on medical history
and/ or centralized review of liver histology.

- History of liver transplantation

- Current or history of hepatocellular carcinoma (HCC)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.